FusionNeoAntigen Logo

Home

Download

Statistics

Examples

Help

Contact

Terms of Use

Center for Computational Systems Medicine
leaf

Fusion Gene and Fusion Protein Summary

leaf

Fusion Amino Acid Sequences (multiple BPs and multiple gene isoforms)

leaf

Fusion Protein Breakpoint Sequences - (for the Screening of the FusionNeoAntigens)

leaf

Potential FusionNeoAntigens in HLA I - (netMHCpan v4.1 + deepHLApan v1.1)

leaf

Potential FusionNeoAntigens in HLA II - (netMHCIIpan v4.1)

leaf

Fusion Breakpoint 14 AA Peptide Structure - (RoseTTAFold)

leaf

Filtering FusionNeoAntigens Through Checking the Interaction with HLAs in 3D - (Glide)

leaf

Vaccine Design for the FusionNeoAntigens (RNA/protein sequences)

leaf

Potential target of CAR-T therapy development

leaf

Information on the samples that have these potential fusion neoantigens

leaf

Fusion Protein Targeting Drugs - (Manual Curation)

leaf

Fusion Protein Related diseases - (Manual Curation)

Fusion Protein:PARN-SMG1

Fusion Gene and Fusion Protein Summary

check button Fusion gene summary
Fusion partner gene informationFusion gene name: PARN-SMG1
FusionPDB ID: 62793
FusionGDB2.0 ID: 62793
HgeneTgene
Gene symbol

PARN

SMG1

Gene ID

5073

23049

Gene namepoly(A)-specific ribonucleaseSMG1 nonsense mediated mRNA decay associated PI3K related kinase
SynonymsDAN|DKCB6|PFBMFT461E3.4|ATX|LIP
Cytomap

16p13.12

16p12.3

Type of geneprotein-codingprotein-coding
Descriptionpoly(A)-specific ribonuclease PARNdeadenylating nucleasedeadenylation nucleasepolyadenylate-specific ribonucleaseserine/threonine-protein kinase SMG1PI-3-kinase-related kinase SMG-1SMG1 phosphatidylinositol 3-kinase-related kinaselambda-interacting proteinlambda/iota protein kinase C-interacting proteinsmg-1 homolog, phosphatidylinositol 3-kinase-related kinase
Modification date2020031320200313
UniProtAcc..
Ensembl transtripts involved in fusion geneENST idsENST00000341484, ENST00000420015, 
ENST00000437198, ENST00000539279, 
ENST00000566021, 
ENST00000565224, 
ENST00000567737, ENST00000389467, 
ENST00000446231, 
Fusion gene scores for assessment (based on all fusion genes of FusionGDB 2.0)* DoF score15 X 15 X 6=135017 X 19 X 7=2261
# samples 1618
** MAII scorelog2(16/1350*10)=-3.07681559705083
possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs).
DoF>8 and MAII<0
log2(18/2261*10)=-3.65089218042185
possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs).
DoF>8 and MAII<0
Fusion gene context

PubMed: PARN [Title/Abstract] AND SMG1 [Title/Abstract] AND fusion [Title/Abstract]

Fusion neoantigen context

PubMed: PARN [Title/Abstract] AND SMG1 [Title/Abstract] AND neoantigen [Title/Abstract]

Most frequent breakpoint (based on all fusion genes of FusionGDB 2.0)PARN(14645878)-SMG1(18849788), # samples:1
Anticipated loss of major functional domain due to fusion event.PARN-SMG1 seems lost the major protein functional domain in Hgene partner, which is a CGC by not retaining the major functional domain in the partially deleted in-frame ORF.
PARN-SMG1 seems lost the major protein functional domain in Hgene partner, which is a CGC by not retaining the major functional domain in the partially deleted in-frame ORF.
PARN-SMG1 seems lost the major protein functional domain in Hgene partner, which is a essential gene by not retaining the major functional domain in the partially deleted in-frame ORF.
PARN-SMG1 seems lost the major protein functional domain in Hgene partner, which is a essential gene by not retaining the major functional domain in the partially deleted in-frame ORF.
PARN-SMG1 seems lost the major protein functional domain in Hgene partner, which is a cell metabolism gene due to the frame-shifted ORF.
PARN-SMG1 seems lost the major protein functional domain in Hgene partner, which is a essential gene due to the frame-shifted ORF.
PARN-SMG1 seems lost the major protein functional domain in Tgene partner, which is a cell metabolism gene due to the frame-shifted ORF.
PARN-SMG1 seems lost the major protein functional domain in Tgene partner, which is a IUPHAR drug target due to the frame-shifted ORF.
PARN-SMG1 seems lost the major protein functional domain in Tgene partner, which is a kinase due to the frame-shifted ORF.
* DoF score (Degree of Frequency) = # partners X # break points X # cancer types
** MAII score (Major Active Isofusion Index) = log2(# samples/DoF score*10)

check button Gene ontology of each fusion partner gene with evidence of Inferred from Direct Assay (IDA) from Entrez
PartnerGeneGO IDGO termPubMed ID
HgenePARN

GO:0000495

box H/ACA snoRNA 3'-end processing

22442037

HgenePARN

GO:0010587

miRNA catabolic process

25049417

HgenePARN

GO:0071051

polyadenylation-dependent snoRNA 3'-end processing

22442037

TgeneSMG1

GO:0000184

nuclear-transcribed mRNA catabolic process, nonsense-mediated decay

11544179

TgeneSMG1

GO:0018105

peptidyl-serine phosphorylation

11544179|15175154

TgeneSMG1

GO:0046777

protein autophosphorylation

11331269|11544179

TgeneSMG1

GO:0046854

phosphatidylinositol phosphorylation

11331269

TgeneSMG1

GO:2001020

regulation of response to DNA damage stimulus

15175154



check button Four levels of functional features of fusion genes
Go to FGviewer search page for the most frequent breakpoint (https://ccsmweb.uth.edu/FGviewer/chr16:14645878/chr16:18849788)
- FGviewer provides the online visualization of the retention search of the protein functional features across DNA, RNA, protein, and pathological levels.
- How to search
1. Put your fusion gene symbol.
2. Press the tab key until there will be shown the breakpoint information filled.
4. Go down and press 'Search' tab twice.
4. Go down to have the hyperlink of the search result.
5. Click the hyperlink.
6. See the FGviewer result for your fusion gene.
FGviewer

check buttonRetention analysis results of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features, are available here.

check buttonFusion gene breakpoints across PARN (5'-gene)
* Click on the image to open the UCSC genome browser with custom track showing this image in a new window.
all structure

check buttonFusion gene breakpoints across SMG1 (3'-gene)
* Click on the image to open the UCSC genome browser with custom track showing this image in a new window.
all structure


Top

Fusion Amino Acid Sequences


check buttonFusion information from ORFfinder translation from full-length transcript sequence from FusionPDB.
HenstTenstHgeneHchrHbpHstrandTgeneTchrTbpTstrandSeq length
(transcript)
BP loci
(transcript)
Predicted start
(transcript)
Predicted stop
(transcript)
Seq length
(amino acids)
ENST00000437198PARNchr1614645878-ENST00000389467SMG1chr1618849788-1024316229155261811
ENST00000437198PARNchr1614645878-ENST00000446231SMG1chr1618849788-1024016229155231810
ENST00000420015PARNchr1614645878-ENST00000389467SMG1chr1618849788-1009714768353801765
ENST00000420015PARNchr1614645878-ENST00000446231SMG1chr1618849788-1009414768353771764
ENST00000539279PARNchr1614645878-ENST00000389467SMG1chr1618849788-968910686249721636
ENST00000539279PARNchr1614645878-ENST00000446231SMG1chr1618849788-968610686249691635

check buttonDeepORF prediction of the coding potential based on the fusion transcript sequence of in-frame fusion genes. DeepORF is a coding potential classifier based on convolutional neural network by comparing the real Ribo-seq data. If the no-coding score < 0.5 and coding score > 0.5, then the in-frame fusion transcript is predicted as being likely translated.
HenstTenstHgeneHchrHbpHstrandTgeneTchrTbpTstrandNo-coding scoreCoding score
ENST00000437198ENST00000389467PARNchr1614645878-SMG1chr1618849788-0.0002113140.9997887
ENST00000437198ENST00000446231PARNchr1614645878-SMG1chr1618849788-0.0003560180.9996439
ENST00000420015ENST00000389467PARNchr1614645878-SMG1chr1618849788-0.0002161810.9997838
ENST00000420015ENST00000446231PARNchr1614645878-SMG1chr1618849788-0.000362790.99963725
ENST00000539279ENST00000389467PARNchr1614645878-SMG1chr1618849788-0.0002220530.999778
ENST00000539279ENST00000446231PARNchr1614645878-SMG1chr1618849788-0.0003691730.9996308

check button Predicted full-length fusion amino acid sequences. For individual full-length fusion transcript sequence from FusionPDB, we ran ORFfinder and chose the longest ORF among all the predicted ones.

Get the fusion protein sequences from here.

Fusion protein sequence information is available in the fasta format.
>FusionGDB ID_FusionGDB isoform ID_FGname_Hgene_Hchr_Hbp_Henst_Tgene_Tchr_Tbp_Tenst_length(fusion AA) seq_BP

Top

Fusion Protein Breakpoint Sequences for PARN-SMG1

check button +/-13 AA sequence from the breakpoints of the fusion protein sequences.
HgeneHchrHbpTgeneTchrTbpLength(fusion protein)BP in fusion proteinPeptide
PARNchr1614645878SMG1chr16188497881068335AFVSLSQPEQVKIGKSLRVPEKVPFR
PARNchr1614645878SMG1chr16188497881476464AFVSLSQPEQVKIGKSLRVPEKVPFR
PARNchr1614645878SMG1chr16188497881622510AFVSLSQPEQVKIGKSLRVPEKVPFR

Top

Potential FusionNeoAntigen Information of PARN-SMG1 in HLA I

check button Multiple sequence alignments of the potential FusionNeoAntigens per fusion breakpoints. If the MSA is empty, then it means that there were predicted fusion neoantigens in this fusion breakpoint, but those predicted fusion neoantigens were not across the breakpoint, which is not fusion-specific.
PARN-SMG1_14645878_18849788.msa

check button Potential FusionNeoAntigen Information
* We used NetMHCpan v4.1 (%rank<0.5) and deepHLApan v1.1 (immunogenic score>0.5)
Fusion geneHchrHbpTgeneTchrTbpHLA IFusionNeoAntigen peptideBinding scoreImmunogenic scoreNeoantigen start (at BP 13)Neoantigen end (at BP 13)
PARN-SMG1chr1614645878chr16188497881476HLA-B39:01EQVKIGKSL0.91110.7142817
PARN-SMG1chr1614645878chr16188497881476HLA-B39:13EQVKIGKSL0.82590.7351817
PARN-SMG1chr1614645878chr16188497881476HLA-B38:02EQVKIGKSL0.82070.7945817
PARN-SMG1chr1614645878chr16188497881476HLA-B13:01EQVKIGKSL0.47250.7954817
PARN-SMG1chr1614645878chr16188497881476HLA-B39:12EQVKIGKSL0.86680.724817
PARN-SMG1chr1614645878chr16188497881476HLA-B39:05EQVKIGKSL0.83560.6761817
PARN-SMG1chr1614645878chr16188497881476HLA-B39:08EQVKIGKSL0.74870.7296817
PARN-SMG1chr1614645878chr16188497881476HLA-B14:03EQVKIGKSL0.71760.6576817
PARN-SMG1chr1614645878chr16188497881476HLA-B07:12QPEQVKIGKSL0.99940.56617
PARN-SMG1chr1614645878chr16188497881476HLA-B42:02QPEQVKIGKSL0.9840.7312617
PARN-SMG1chr1614645878chr16188497881476HLA-B42:01QPEQVKIGKSL0.9840.7252617
PARN-SMG1chr1614645878chr16188497881476HLA-B39:10QPEQVKIGKSL0.84480.9142617
PARN-SMG1chr1614645878chr16188497881476HLA-B39:02EQVKIGKSL0.89710.7397817
PARN-SMG1chr1614645878chr16188497881476HLA-B39:31EQVKIGKSL0.89710.7168817
PARN-SMG1chr1614645878chr16188497881476HLA-B39:11EQVKIGKSL0.71210.6701817
PARN-SMG1chr1614645878chr16188497881476HLA-B15:73EQVKIGKSL0.60920.5526817
PARN-SMG1chr1614645878chr16188497881476HLA-B15:54EQVKIGKSL0.59760.6489817
PARN-SMG1chr1614645878chr16188497881476HLA-B15:30EQVKIGKSL0.55220.5579817
PARN-SMG1chr1614645878chr16188497881476HLA-B15:53EQVKIGKSL0.47660.6737817
PARN-SMG1chr1614645878chr16188497881476HLA-C06:08VKIGKSLRV0.37990.95981019
PARN-SMG1chr1614645878chr16188497881476HLA-B18:04EQVKIGKSL0.28190.7267817
PARN-SMG1chr1614645878chr16188497881476HLA-B15:12EQVKIGKSL0.24180.7233817
PARN-SMG1chr1614645878chr16188497881476HLA-C06:02VKIGKSLRV0.00870.96631019
PARN-SMG1chr1614645878chr16188497881476HLA-C06:17VKIGKSLRV0.00870.96631019
PARN-SMG1chr1614645878chr16188497881476HLA-B67:01QPEQVKIGKSL0.86390.8118617

Top

Potential FusionNeoAntigen Information of PARN-SMG1 in HLA II

check button Multiple sequence alignments of the potential FusionNeoAntigens per fusion breakpoints. If the MSA is empty, then it means that there were predicted fusion neoantigens in this fusion breakpoint, but those predicted fusion neoantigens were not across the breakpoint, which is not fusion-specific.
PARN-SMG1_14645878_18849788.msa

check button Potential FusionNeoAntigen Information
* We used NetMHCIIpan v4.1 (%rank<0.5).
Fusion geneHchrHbpTgeneTchrTbpHLA IIFusionNeoAntigen peptideNeoantigen start (at BP 13)Neoantigen end (at BP 13)
PARN-SMG1chr1614645878chr16188497881476DRB1-0102PEQVKIGKSLRVPEK722
PARN-SMG1chr1614645878chr16188497881476DRB1-0102QPEQVKIGKSLRVPE621
PARN-SMG1chr1614645878chr16188497881476DRB1-0103PEQVKIGKSLRVPEK722
PARN-SMG1chr1614645878chr16188497881476DRB1-0109PEQVKIGKSLRVPEK722
PARN-SMG1chr1614645878chr16188497881476DRB1-0115PEQVKIGKSLRVPEK722
PARN-SMG1chr1614645878chr16188497881476DRB1-0123PEQVKIGKSLRVPEK722
PARN-SMG1chr1614645878chr16188497881476DRB1-0123QPEQVKIGKSLRVPE621
PARN-SMG1chr1614645878chr16188497881476DRB1-0701PEQVKIGKSLRVPEK722
PARN-SMG1chr1614645878chr16188497881476DRB1-0701QPEQVKIGKSLRVPE621
PARN-SMG1chr1614645878chr16188497881476DRB1-0703PEQVKIGKSLRVPEK722
PARN-SMG1chr1614645878chr16188497881476DRB1-0703QPEQVKIGKSLRVPE621
PARN-SMG1chr1614645878chr16188497881476DRB1-0704PEQVKIGKSLRVPEK722
PARN-SMG1chr1614645878chr16188497881476DRB1-0704QPEQVKIGKSLRVPE621
PARN-SMG1chr1614645878chr16188497881476DRB1-0705PEQVKIGKSLRVPEK722
PARN-SMG1chr1614645878chr16188497881476DRB1-0705QPEQVKIGKSLRVPE621
PARN-SMG1chr1614645878chr16188497881476DRB1-0706PEQVKIGKSLRVPEK722
PARN-SMG1chr1614645878chr16188497881476DRB1-0706QPEQVKIGKSLRVPE621
PARN-SMG1chr1614645878chr16188497881476DRB1-0707PEQVKIGKSLRVPEK722
PARN-SMG1chr1614645878chr16188497881476DRB1-0707QPEQVKIGKSLRVPE621
PARN-SMG1chr1614645878chr16188497881476DRB1-0708PEQVKIGKSLRVPEK722
PARN-SMG1chr1614645878chr16188497881476DRB1-0708QPEQVKIGKSLRVPE621
PARN-SMG1chr1614645878chr16188497881476DRB1-0709PEQVKIGKSLRVPEK722
PARN-SMG1chr1614645878chr16188497881476DRB1-0709QPEQVKIGKSLRVPE621
PARN-SMG1chr1614645878chr16188497881476DRB1-0711PEQVKIGKSLRVPEK722
PARN-SMG1chr1614645878chr16188497881476DRB1-0712PEQVKIGKSLRVPEK722
PARN-SMG1chr1614645878chr16188497881476DRB1-0712QPEQVKIGKSLRVPE621
PARN-SMG1chr1614645878chr16188497881476DRB1-0713PEQVKIGKSLRVPEK722
PARN-SMG1chr1614645878chr16188497881476DRB1-0713QPEQVKIGKSLRVPE621
PARN-SMG1chr1614645878chr16188497881476DRB1-0714PEQVKIGKSLRVPEK722
PARN-SMG1chr1614645878chr16188497881476DRB1-0714QPEQVKIGKSLRVPE621
PARN-SMG1chr1614645878chr16188497881476DRB1-0715PEQVKIGKSLRVPEK722
PARN-SMG1chr1614645878chr16188497881476DRB1-0715QPEQVKIGKSLRVPE621
PARN-SMG1chr1614645878chr16188497881476DRB1-0716PEQVKIGKSLRVPEK722
PARN-SMG1chr1614645878chr16188497881476DRB1-0716QPEQVKIGKSLRVPE621
PARN-SMG1chr1614645878chr16188497881476DRB1-0717PEQVKIGKSLRVPEK722
PARN-SMG1chr1614645878chr16188497881476DRB1-0717QPEQVKIGKSLRVPE621
PARN-SMG1chr1614645878chr16188497881476DRB1-0719PEQVKIGKSLRVPEK722
PARN-SMG1chr1614645878chr16188497881476DRB1-0719QPEQVKIGKSLRVPE621
PARN-SMG1chr1614645878chr16188497881476DRB1-0819PEQVKIGKSLRVPEK722
PARN-SMG1chr1614645878chr16188497881476DRB1-0834PEQVKIGKSLRVPEK722
PARN-SMG1chr1614645878chr16188497881476DRB1-0901PEQVKIGKSLRVPEK722
PARN-SMG1chr1614645878chr16188497881476DRB1-0901QPEQVKIGKSLRVPE621
PARN-SMG1chr1614645878chr16188497881476DRB1-0902PEQVKIGKSLRVPEK722
PARN-SMG1chr1614645878chr16188497881476DRB1-0903PEQVKIGKSLRVPEK722
PARN-SMG1chr1614645878chr16188497881476DRB1-0903QPEQVKIGKSLRVPE621
PARN-SMG1chr1614645878chr16188497881476DRB1-0904PEQVKIGKSLRVPEK722
PARN-SMG1chr1614645878chr16188497881476DRB1-0904QPEQVKIGKSLRVPE621
PARN-SMG1chr1614645878chr16188497881476DRB1-0905PEQVKIGKSLRVPEK722
PARN-SMG1chr1614645878chr16188497881476DRB1-0905QPEQVKIGKSLRVPE621
PARN-SMG1chr1614645878chr16188497881476DRB1-0906PEQVKIGKSLRVPEK722
PARN-SMG1chr1614645878chr16188497881476DRB1-0906QPEQVKIGKSLRVPE621
PARN-SMG1chr1614645878chr16188497881476DRB1-0906SQPEQVKIGKSLRVP520
PARN-SMG1chr1614645878chr16188497881476DRB1-0906EQVKIGKSLRVPEKV823
PARN-SMG1chr1614645878chr16188497881476DRB1-0907PEQVKIGKSLRVPEK722
PARN-SMG1chr1614645878chr16188497881476DRB1-0907QPEQVKIGKSLRVPE621
PARN-SMG1chr1614645878chr16188497881476DRB1-0909PEQVKIGKSLRVPEK722
PARN-SMG1chr1614645878chr16188497881476DRB1-0909QPEQVKIGKSLRVPE621
PARN-SMG1chr1614645878chr16188497881476DRB1-1220PEQVKIGKSLRVPEK722
PARN-SMG1chr1614645878chr16188497881476DRB1-1221PEQVKIGKSLRVPEK722
PARN-SMG1chr1614645878chr16188497881476DRB1-1331PEQVKIGKSLRVPEK722
PARN-SMG1chr1614645878chr16188497881476DRB1-1354PEQVKIGKSLRVPEK722
PARN-SMG1chr1614645878chr16188497881476DRB1-1367PEQVKIGKSLRVPEK722
PARN-SMG1chr1614645878chr16188497881476DRB1-1376PEQVKIGKSLRVPEK722
PARN-SMG1chr1614645878chr16188497881476DRB1-1377PEQVKIGKSLRVPEK722
PARN-SMG1chr1614645878chr16188497881476DRB1-1381QVKIGKSLRVPEKVP924
PARN-SMG1chr1614645878chr16188497881476DRB1-1389QVKIGKSLRVPEKVP924
PARN-SMG1chr1614645878chr16188497881476DRB1-1404PEQVKIGKSLRVPEK722
PARN-SMG1chr1614645878chr16188497881476DRB1-1410PEQVKIGKSLRVPEK722
PARN-SMG1chr1614645878chr16188497881476DRB1-1410QPEQVKIGKSLRVPE621
PARN-SMG1chr1614645878chr16188497881476DRB1-1411PEQVKIGKSLRVPEK722
PARN-SMG1chr1614645878chr16188497881476DRB1-1416PEQVKIGKSLRVPEK722
PARN-SMG1chr1614645878chr16188497881476DRB1-1418PEQVKIGKSLRVPEK722
PARN-SMG1chr1614645878chr16188497881476DRB1-1428PEQVKIGKSLRVPEK722
PARN-SMG1chr1614645878chr16188497881476DRB1-1428QPEQVKIGKSLRVPE621
PARN-SMG1chr1614645878chr16188497881476DRB1-1429PEQVKIGKSLRVPEK722
PARN-SMG1chr1614645878chr16188497881476DRB1-1431PEQVKIGKSLRVPEK722
PARN-SMG1chr1614645878chr16188497881476DRB1-1438PEQVKIGKSLRVPEK722
PARN-SMG1chr1614645878chr16188497881476DRB1-1439PEQVKIGKSLRVPEK722
PARN-SMG1chr1614645878chr16188497881476DRB1-1439QPEQVKIGKSLRVPE621
PARN-SMG1chr1614645878chr16188497881476DRB1-1448PEQVKIGKSLRVPEK722
PARN-SMG1chr1614645878chr16188497881476DRB1-1450PEQVKIGKSLRVPEK722
PARN-SMG1chr1614645878chr16188497881476DRB1-1450QPEQVKIGKSLRVPE621
PARN-SMG1chr1614645878chr16188497881476DRB1-1455PEQVKIGKSLRVPEK722
PARN-SMG1chr1614645878chr16188497881476DRB1-1457PEQVKIGKSLRVPEK722
PARN-SMG1chr1614645878chr16188497881476DRB1-1457QPEQVKIGKSLRVPE621
PARN-SMG1chr1614645878chr16188497881476DRB1-1461PEQVKIGKSLRVPEK722
PARN-SMG1chr1614645878chr16188497881476DRB1-1470PEQVKIGKSLRVPEK722
PARN-SMG1chr1614645878chr16188497881476DRB1-1470QPEQVKIGKSLRVPE621
PARN-SMG1chr1614645878chr16188497881476DRB1-1471PEQVKIGKSLRVPEK722
PARN-SMG1chr1614645878chr16188497881476DRB1-1475PEQVKIGKSLRVPEK722
PARN-SMG1chr1614645878chr16188497881476DRB1-1481PEQVKIGKSLRVPEK722
PARN-SMG1chr1614645878chr16188497881476DRB1-1482PEQVKIGKSLRVPEK722
PARN-SMG1chr1614645878chr16188497881476DRB1-1499PEQVKIGKSLRVPEK722
PARN-SMG1chr1614645878chr16188497881476DRB1-1501PEQVKIGKSLRVPEK722
PARN-SMG1chr1614645878chr16188497881476DRB1-1504PEQVKIGKSLRVPEK722
PARN-SMG1chr1614645878chr16188497881476DRB1-1504QPEQVKIGKSLRVPE621
PARN-SMG1chr1614645878chr16188497881476DRB1-1505PEQVKIGKSLRVPEK722
PARN-SMG1chr1614645878chr16188497881476DRB1-1506PEQVKIGKSLRVPEK722
PARN-SMG1chr1614645878chr16188497881476DRB1-1507PEQVKIGKSLRVPEK722
PARN-SMG1chr1614645878chr16188497881476DRB1-1507QPEQVKIGKSLRVPE621
PARN-SMG1chr1614645878chr16188497881476DRB1-1509PEQVKIGKSLRVPEK722
PARN-SMG1chr1614645878chr16188497881476DRB1-1510PEQVKIGKSLRVPEK722
PARN-SMG1chr1614645878chr16188497881476DRB1-1513PEQVKIGKSLRVPEK722
PARN-SMG1chr1614645878chr16188497881476DRB1-1516PEQVKIGKSLRVPEK722
PARN-SMG1chr1614645878chr16188497881476DRB1-1518PEQVKIGKSLRVPEK722
PARN-SMG1chr1614645878chr16188497881476DRB1-1520PEQVKIGKSLRVPEK722
PARN-SMG1chr1614645878chr16188497881476DRB1-1521PEQVKIGKSLRVPEK722
PARN-SMG1chr1614645878chr16188497881476DRB1-1522PEQVKIGKSLRVPEK722
PARN-SMG1chr1614645878chr16188497881476DRB1-1523PEQVKIGKSLRVPEK722
PARN-SMG1chr1614645878chr16188497881476DRB1-1524PEQVKIGKSLRVPEK722
PARN-SMG1chr1614645878chr16188497881476DRB1-1525PEQVKIGKSLRVPEK722
PARN-SMG1chr1614645878chr16188497881476DRB1-1525QPEQVKIGKSLRVPE621
PARN-SMG1chr1614645878chr16188497881476DRB1-1528PEQVKIGKSLRVPEK722
PARN-SMG1chr1614645878chr16188497881476DRB1-1532PEQVKIGKSLRVPEK722
PARN-SMG1chr1614645878chr16188497881476DRB1-1533PEQVKIGKSLRVPEK722
PARN-SMG1chr1614645878chr16188497881476DRB1-1535PEQVKIGKSLRVPEK722
PARN-SMG1chr1614645878chr16188497881476DRB1-1536PEQVKIGKSLRVPEK722
PARN-SMG1chr1614645878chr16188497881476DRB1-1537PEQVKIGKSLRVPEK722
PARN-SMG1chr1614645878chr16188497881476DRB1-1540PEQVKIGKSLRVPEK722
PARN-SMG1chr1614645878chr16188497881476DRB1-1541PEQVKIGKSLRVPEK722
PARN-SMG1chr1614645878chr16188497881476DRB1-1542PEQVKIGKSLRVPEK722
PARN-SMG1chr1614645878chr16188497881476DRB1-1543PEQVKIGKSLRVPEK722
PARN-SMG1chr1614645878chr16188497881476DRB1-1545PEQVKIGKSLRVPEK722
PARN-SMG1chr1614645878chr16188497881476DRB1-1546PEQVKIGKSLRVPEK722
PARN-SMG1chr1614645878chr16188497881476DRB1-1548PEQVKIGKSLRVPEK722
PARN-SMG1chr1614645878chr16188497881476DRB1-1548QPEQVKIGKSLRVPE621
PARN-SMG1chr1614645878chr16188497881476DRB1-1549PEQVKIGKSLRVPEK722
PARN-SMG1chr1614645878chr16188497881476DRB1-1615PEQVKIGKSLRVPEK722
PARN-SMG1chr1614645878chr16188497881476DRB1-1615QPEQVKIGKSLRVPE621
PARN-SMG1chr1614645878chr16188497881476DRB3-0201PEQVKIGKSLRVPEK722
PARN-SMG1chr1614645878chr16188497881476DRB3-0201QPEQVKIGKSLRVPE621
PARN-SMG1chr1614645878chr16188497881476DRB3-0204PEQVKIGKSLRVPEK722
PARN-SMG1chr1614645878chr16188497881476DRB3-0204QPEQVKIGKSLRVPE621
PARN-SMG1chr1614645878chr16188497881476DRB3-0209PEQVKIGKSLRVPEK722
PARN-SMG1chr1614645878chr16188497881476DRB3-0221PEQVKIGKSLRVPEK722
PARN-SMG1chr1614645878chr16188497881476DRB3-0224PEQVKIGKSLRVPEK722
PARN-SMG1chr1614645878chr16188497881476DRB3-0224QPEQVKIGKSLRVPE621
PARN-SMG1chr1614645878chr16188497881476DRB3-0301PEQVKIGKSLRVPEK722
PARN-SMG1chr1614645878chr16188497881476DRB3-0301QPEQVKIGKSLRVPE621
PARN-SMG1chr1614645878chr16188497881476DRB5-0106PEQVKIGKSLRVPEK722
PARN-SMG1chr1614645878chr16188497881476DRB5-0112PEQVKIGKSLRVPEK722
PARN-SMG1chr1614645878chr16188497881476DRB5-0204PEQVKIGKSLRVPEK722
PARN-SMG1chr1614645878chr16188497881476DRB5-0205PEQVKIGKSLRVPEK722

Top

Fusion breakpoint peptide structures of PARN-SMG1

check button3D structures of the fusion breakpoint peptide of 14AA sequence that have potential fusion neoantigens
* The minimum length of the amino acid sequence in RoseTTAFold is 14AA. Here, we predicted the 14AA fusion protein breakpoint sequence not the fusion neoantigen peptide, which is shorter than 14 AA.
File nameBPseqHgeneTgeneHchrHbpTchrTbpAAlen
7453QPEQVKIGKSLRVPPARNSMG1chr1614645878chr16188497881476

Top

Filtering FusionNeoAntigens Through Checking the Interaction with HLAs in 3D of PARN-SMG1

check buttonVirtual screening between 25 HLAs (from PDB) and FusionNeoAntigens
* We used Glide to predict the interaction between HLAs and neoantigens.
HLA allelePDB IDFile nameBPseqDocking scoreGlide score
HLA-B14:023BVN7453QPEQVKIGKSLRVP-7.9962-8.1096
HLA-B14:023BVN7453QPEQVKIGKSLRVP-5.70842-6.74372
HLA-B52:013W397453QPEQVKIGKSLRVP-6.83737-6.95077
HLA-B52:013W397453QPEQVKIGKSLRVP-4.4836-5.5189
HLA-A11:014UQ27453QPEQVKIGKSLRVP-10.0067-10.1201
HLA-A11:014UQ27453QPEQVKIGKSLRVP-9.03915-10.0745
HLA-A24:025HGA7453QPEQVKIGKSLRVP-6.56204-6.67544
HLA-A24:025HGA7453QPEQVKIGKSLRVP-5.42271-6.45801
HLA-B44:053DX87453QPEQVKIGKSLRVP-7.85648-8.89178
HLA-B44:053DX87453QPEQVKIGKSLRVP-5.3978-5.5112
HLA-A02:016TDR7453QPEQVKIGKSLRVP-3.37154-4.40684

Top

Vaccine Design for the FusionNeoAntigens of PARN-SMG1

check button mRNA and peptide sequences of FusionNeoAntigens that have potential interaction with HLA-Is.
Fusion geneHchrHbpTchrTbpStart in +/-13AAEnd in +/-13AAFusionNeoAntigen peptide sequenceFusionNeoAntigen RNA sequence
PARN-SMG1chr1614645878chr16188497881019VKIGKSLRVTAAAGATTGGTAAAAGCCTTAGAGTTC
PARN-SMG1chr1614645878chr1618849788617QPEQVKIGKSLAGCCCGAGCAAGTAAAGATTGGTAAAAGCCTTA
PARN-SMG1chr1614645878chr1618849788817EQVKIGKSLAGCAAGTAAAGATTGGTAAAAGCCTTA

check button mRNA and peptide sequences of FusionNeoAntigens that have potential interaction with HLA-IIs.
Fusion geneHchrHbpTchrTbpStart in +/-13AAEnd in +/-13AAFusionNeoAntigen peptideFusionNEoAntigen RNA sequence
PARN-SMG1chr1614645878chr1618849788520SQPEQVKIGKSLRVPGCCAGCCCGAGCAAGTAAAGATTGGTAAAAGCCTTAGAGTTCCTG
PARN-SMG1chr1614645878chr1618849788621QPEQVKIGKSLRVPEAGCCCGAGCAAGTAAAGATTGGTAAAAGCCTTAGAGTTCCTGAGA
PARN-SMG1chr1614645878chr1618849788722PEQVKIGKSLRVPEKCCGAGCAAGTAAAGATTGGTAAAAGCCTTAGAGTTCCTGAGAAAG
PARN-SMG1chr1614645878chr1618849788823EQVKIGKSLRVPEKVAGCAAGTAAAGATTGGTAAAAGCCTTAGAGTTCCTGAGAAAGTAC
PARN-SMG1chr1614645878chr1618849788924QVKIGKSLRVPEKVPAAGTAAAGATTGGTAAAAGCCTTAGAGTTCCTGAGAAAGTACCTT

Top

Information of the samples that have these potential fusion neoantigens of PARN-SMG1

check button These samples were reported as having these fusion breakpoints. For individual breakpoints, we checked the open reading frames considering multiple gene isoforms and chose the in-frame fusion genes only. Then, we made fusion protein sequences and predicted the fusion neoantigens. These fusion-positive samples may have these potential fusion neoantigens.
Cancer typeFusion geneHchrHbpHenstTchrTbpTenstSample
BRCAPARN-SMG1chr1614645878ENST00000420015chr1618849788ENST00000389467TCGA-S3-AA0Z-01A

Top

Potential target of CAR-T therapy development for PARN-SMG1

check button Predicted 3D structure. We used RoseTTAFold.

check buttonRetention analysis result of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features. Here, to provide the retention of the transmembrane domain, we only show the protein feature retention information of those transmembrane features


* Minus value of BPloci means that the break point is located before the CDS.
- In-frame and retained 'Transmembrane'.
PartnerGeneHbpTbpENSTStrandBPexonTotalExonProtein feature loci*BPlociTotalLenProtein featureProtein feature note

check button Subcellular localization prediction of the transmembrane domain retained fusion proteins
* We used DeepLoc 1.0. The order of the X-axis of the barplot is as follows: Entry_ID, Localization, Type, Nucleus, Cytoplasm, Extracellular, Mitochondrion, Cell_membrane, Endoplasmic_reticulum, Plastid, Golgi.apparatus, Lysosome.Vacuole, Peroxisome. Y-axis is the output score of DeepLoc. Clicking the image will open a new tab with a large image.
HgeneHchrHbpHenstTgeneTchrTbpTenstDeepLoc result

Top

Related Drugs to PARN-SMG1

check button Drugs used for this fusion-positive patient.
(Manual curation of PubMed, 04-30-2022 + MyCancerGenome)
HgeneTgeneDrugSourcePMID

Top

Related Diseases to PARN-SMG1

check button Diseases that have this fusion gene.
(Manual curation of PubMed, 04-30-2022 + MyCancerGenome)
HgeneTgeneDiseaseSourcePMID

check button Diseases associated with fusion partners.
(DisGeNet 4.0)
PartnerGeneDisease IDDisease name# pubmedsSource